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1. Introduction 
One player in health cognitive functioning is shown to be lipoproteins, essential in the 
metabolism and redistribution of lipids: cholesterol, phospholipids and triacylglycerol. 
There are several classes of lipoproteins which are used to transport lipids throughout the 
body and range in density (protein/lipid ratio); chylomicrons (contain dietary lipids), 
intermediate low density lipoproteins (IDL), very low density lipoproteins (VLDL, bad 
cholesterol), low density lipoproteins (LDLs) and the high density lipoproteins (HDLs, good 
cholesterol). The Apolipoprotein/Apoprotein gene family of proteins is part of the 
lipoprotein complexes that function as regulators of binding between lipoproteins and 
receptors. These proteins act as enzyme co-factors during lipid metabolism, helping to 
stabilize lipoproteins during transportation from cell or tissue to its destination [1].  
Apolipoprotein E (ApoE), initially termed the “arginine-rich apoprotein”, was first 
identified as a part of the VLDL complexes. ApoE is synthesized principally in the liver, but 
has also been found in other tissues such as the brain, ovaries, lungs, adrenals, spleen, 
muscle cells, and macrophages [2]. The three most common alleles of ApoE are ApoE2, 
ApoE3, ApoE4 [3] found in the nervous system are primarily produced in astroglia and 
microglia. The three major isoforms differ at position 112 (ApoE2/ApoE3 Cysteine, ApoE4 
Arginine) and 158 (ApoE2 Cysteine, ApoE3/ApoE4 Arginine), the amino acid substitutions at 
position 112 affect salt bridge formation within the protein, which ultimately impacts on 
lipoprotein preference, stability of the protein and on receptor binding activities of the 
isoforms [4]. Being an ApoE4 carrier or having the ApoE2/ApoE3 genotype is associated with 
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higher triglyercide levels, higher VLDL levels, higher total cholesterol, higher total 
lipoproteins levels and elevated LDL or “bad cholesterol” levels all of which contribute to 
hypertension and diabetes confounding factors that have to be considered when designing a 
chemotherapy treatment regiment [5].  
In rodent models, the lack of ApoE or ApoE4 protein expression leads to destabilization of 
cell membranes, increased apoptosis, and heightened sensitivity to neuronal trauma; 
whereas, ApoE3 and ApoE2 protein expression allow for healthy cell functioning and 
neuroprotection [4]. ApoE4 has detrimental effects in transgenic mice, including behavioral 
abnormalities, such as deficits in spatial learning and memory using Morris water maze 
(MWM) [6], as well as significant alterations in the hippocampus and cortex [4,7]. The 
studies in mice are consistent with clinical studies indicating reduced spatial learning and 
memory in those who carry the ApoE4 allele [8]. Experiments have also demonstrated that 
the three isoforms of human ApoE gene have different effects on the development of 
neurodegenerative diseases. Those individuals that are ApoE4 carriers have an increased 
risk of age-related mild cognitive impairments (MCI) and the development of Alzheimer’s 
disease (AD) particularly in females [9].  
In ovarian cancer, ApoE protein levels act as a potential tumor-associated marker as found 
in serous carcinomas, but not in serious borderline or normal ovarian surface epithelium 
cells [10]. Up-regulation of ApoE protein levels is also seen in breast carcinomas, pancreatic 
cancer, stomach carcinomas, colon carcinomas and prostate carcinomas [10]. Blockage of 
ApoE expression in the serous carcinoma cell lines leads to cell cycle arrest and apoptosis. 
Women infused with ApoE protein at the time of diagnosis showed significantly higher 
survival rates [10]. This data suggest that upregulation of ApoE expression may be a defense 
mechanism to help body fight carcinomas. 
2. Chemotherapy, ApoE and memory 
Over the last 20 years it has become apparent that chemotherapy drugs not only attack 
cancer cells, but also cross the blood brain barrier (BBB) leading to negative effects on 
cognitive processing which is known as Chemo-brain or Chem-fog [11,12]. Methotrexate, 5-
Flourouracil (5-FU) the most common chemotherapy drugs used to treat breast, colorectal, 
head and neck cancers been shown in both rodent models and clinical studies to lead to 
neurocognitive deficits in a variety of domains including visual memory and visuospatial 
functioning [11,13,14]. In clinical studies, there is considerable variability between studies as 
to the extent and frequency of such impairments heretofore mentioned. However, rodent 
studies are clearly show that the drugs in the CMF (cyclophosphamide, methotrexate, 5-FU) 
regiment lead to decreased hippocampus cell proliferation and induce MWM memory 
impairments [15,16]. In addition, cytarabine (cytosine arabinoside) and ifosfamide among 
other chemotherapy have been shown to lead to memory impairments, hemiparesis, aphasia 
and progressive dementia [17]. However, there is significant lack of pre-clinical testing of 
most chemotherapeutic agents and their long-term effects on memory. 
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Currently, only one study has examined if ApoE4 carrier status as a potential genetic risk 
factor in breast or lymphoma survivors. They have found that even after 8 years, ApoE4 
carriers displayed impairments, specifically in visual memory and spatial ability [18]. This 
suggests that the ApoE genotype may be a confounding factor to consider when examining 
post-chemotherapy neurocognitive status. More studies are necessary to confirm this 
result. 
Studies in women treated with CMF regiment for breast cancer found increased total 
cholesterol, LDL, HDL cholesterol and Apolipoprotein A-1 (ApoA-1) in those who 
developed permanent amenorrhea (loss of menstrual cycle, induced menopause) [19]. 
Studies report that around 30% of patients who have gone through chemotherapy develop 
permanent amenorrhea [20]. There is evidence that ApoE4 carriers have an earlier onset of 
natural menopause [21]. Age of menopause and being an ApoE4 carrier are both risk factors 
for age related diseases including AD and coronary artery disease (CAD). There is also a 
direct connection between ApoE mRNA levels and estrogen in various tissues, including the 
brain [22] leading to regulation of neurite outgrowth [7]. The data suggests that ApoE is a 
critical intermediary in the estrogen related neuroplasticity [7]. Lack of estrogen along with 
expression of ApoE4 protein which has reduced ApoE functioning is one potential cause of 
impaired cognitive performance in some women that have undergone chemotherapy. 
Studies do not take this factor into account or narrowly examine menopausal status at the 
time of testing.  
3. Apolipoproteins effects on secondary drug response 
3.1. Tamoxifen  
Other confounding factors that can affect cognitive status after chemotherapy include other 
medications patients are taking to control comorbid conditions or to treat the tumor itself. 
Tamoxifen is used as an estrogen receptor modulator (SERM) in estrogen receptor (ER) 
positive breast cancer carcinomas. Tamoxifen is a pure estrogen receptor blocker. As with 
other drugs, tamoxifen and its metabolites can cross the BBB affecting ER in various brain 
regions including the cerebral cortex, hippocampus and amygdala [23]. In combination with 
chemotherapy, tamoxifen appears to intensify the cognitive impairments, particularly in 
visual memory, verbal working memory and visuospatial ability [24]. The Anatrozole, 
Tamoxifen Combined (ATAC) trial, also found verbal memory and processing speed 
impairments post-chemotherapy treated only with tamoxifen compared to women only on a 
combined ATAC treatment (Table 1) [25]. This suggests that tamoxifen has confounding 
effects when given as part of the chemotherapy regiment. Tamoxifen also appears to have 
both agonist and antagonist properties in the brain with reported up-regulation of pro-
inflammatory cytokines shown to be related to cognitive dysfunction [26]. Positron emission 
tomography (PET) imaging of survivors does show higher hypometabolism with dual 
chemotherapy and tamoxifen, not seen in women treated only with tamoxifen [27]. Animal 
models using repeated tamoxifen or combinations of methotrexate and 5-FU injections both 
produced deficits in acquisition and retention in an operant learning paradigm (Table 1) 
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[28]. These studies were conducted when women were still in treatment, leaving the 
question of potential long-term effects. There is a study that examined women who used 
tamoxifen for <4 years compared to >6 years of exposure. The study found that the current 
exposure led to greater memory deficits compared to non-users (Table 1) [29]. This suggests 
that while on therapy, patients may have acute memory impairments and that alternative 
drugs should be seriously considered.  
In breast cancer survivors undergoing tamoxifen treatment, their total cholesterol, VLDL, 
high density lipoproteins (HDL) and Apolipoprotein B (ApoB) protein levels have been 
shown to decrease in both ApoE4 carriers and non-ApoE4 carriers (Table 1) [30,31]. Breast 
cancer patients who are ApoE4 carriers have higher plasma triglyceride levels and altered 
ApoA-1/ApoB ratio. Both are risk factors for cardiovascular events, after tamoxifen 
treatment (Table 1) [30,31]. In non-ApoE4 carriers, there were lower levels of lipoprotein (a) 
after treatment, but no effect on triglycerides or the ApoA-1/ApoB ratio (Table 1). This 
suggests that non-ApoE4 carriers have a more positive response to tamoxifen with respect to 
lipid profiles and risk for cardiovascular complications [31]. Considering tamoxifen and 
ApoE4 both have a deleterious effect on cognition and tamoxifen has an ApoE genotype 
dependent effect on lipid profiles, suggest further investigations are warranted to 
understand the mechanistic relationship. 
3.2. Anatrozole 
Anatrozole also known as arimidex is an aromatase inhibitor that lowers estrogen levels and 
is used as a treatment in estrogen positive breast cancer patients post-surgery. Results of the 
ATAC trial of 9399 women indicated that those only on arimidex had better clinical 
outcomes including vascular events and gynecological problems compared to the tamoxifen 
group with no differences seen in cognitive outcomes [25,32]. There data suggests that 
arimidex was the preferred initial treatment by women treated for breast cancer [32]. 
However, other studies indicate that women on arimidex treatment had greater cognitive 
decline than tamoxifen treatment in verbal and visual memory (Table 1) [33,34]. At this 
point no effects have been seen on cholesterol, lipoproteins or apolipoprotein levels in both 
animal models and clinical studies (Table 1) [35,36]. Although, there are not alternations in 
lipids levels, the cognitive side effects are of concern with this medication and should be 
examined with respect to ApoE genotype. 
3.3. Letrozole 
Letrozole, a potent aromatase interfering with adrenal steroid biosynthesis, has also been 
assessed as a replacement for tamoxifen or as secondary maintenance treatment after 
tamoxifen as part of the Breast International Group (BIG 1-98) trial [37,38]. In the BIG 1-98 
study, better overall cognitive outcomes were seen in women on letrozole treatment 
compared to those on a tamoxifen treatment (Table 1) [37,38]. In the tamoxifen only group, 
increased endometrial cancer and vaginal bleeding where found [38]. Participants given 
letrozole only did displayed more incidences of skeletal and cardiac events and 
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hypercholesterolemia compared to the tamoxifen group [37]. After letrozole treatment, 
unfavorable effects have been seen including increased serum total cholesterol, LDL and 
ApoB with atherogenic ratio risk of total cholesterol/HDL and LDL/HDL levels (Table 1) 
[39]. Therefore, the better cognitive outcomes may not out-weigh negative effects on 
lipoprotein levels, particularly in those with or at risk for hypertension and/or diabetes. The 
potential confounding factor of ApoE genotype has not been reported. 
3.4. Exemestane 
There is another alternative for estrogen suppression therapy exemestane, an aromatase 
inhibitor, general used after tamoxifen is not working in post-menopausal women. 
Exemestane has been examined as part of the randomized Tamoxifen and Exemestane 
Adjunctive Multinational (TEAM) trial [24]. The preliminary data from the TEAM trial 
found that tamoxifen is associated with lower verbal and executive function, while 
exemestane did not seem to alter cognitive performance levels (Table 1) [24]. Analysis of 
data from 72 patients as part of the EORTC trail 10958 indicates that treatment with 
exemestane resulted in reduced triglyceride levels and tamoxifen treatment increased 
triglyceride levels [40]. All other lipid parameters including HDL, ApoA-1, ApoB or Lip (a) 
levels at 8, 24 and 48 weeks were unchanged by either treatment [40]. Further studies will be 
needed to determine if stable cognitive performance and lipid levels are effect of ApoE 
genotype.  
3.5. Raloxifene 
Raloxifene, also a SERM and is used as a hormone replacement therapy, has the positive 
effects of estrogen on the skeletal system and is an antagonist of estrogen in breast or 
endometrial tissues [41]. Raloxifene treatment also appears to be less detrimental to 
cognitive function assessed by Modified Mini-Mental State (3MS) compared to tamoxifen 
[42]. Used to prevent osteoporosis, it has been shown that after three years of treatment 
raloxifene did not affect overall cognitive scores [43]. The Multiple Outcomes of Raloxifene 
Evaluation (MORE) study of 7478 women, reported finding that raloxifene treatment 
lowered the risk of cognitive decline in word list recall test and there was no overall effect 
on cognitive function (Table 1) [44]. A subset of the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) Study of Tamoxifen and Raloxifene (STAR), the CoSTAR study for 
women at high risk for breast cancer did not find any cognitive effects of either drug (Table 
1) [45]. Together the evidence supports that raloxifene treatment does not impair cognitive 
function the way that tamoxifen treatment and in fact may even lower the risk of cognitive 
decline [34]. 
With respect to lipid and lipoprotein levels post hoc analysis of 2659 women in the MORE 
study, found that raloxifene treatment in women with or without high triglycerides lead 
to reduced cholesterol levels with healthier lipoprotein parameters (Table 1) [46]. Studies 
in Greek women, found that LDL cholesterol levels were lower in women treated with 
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raloxifene [47]. Raloxifene also appears to raise HDL levels and ApoA-1 while decreasing 
ApoB protein levels and improving ratios of total cholesterol to lipoproteins (Table 1). 
After one year of treatment with raloxifene women had reduced fat mass and trunk and 
central regions along with decreased adiposity in their truck and abdominal regions 
(Table 1) [48]. Overall, raloxifene treatment improves cholesterol health and alters fat 
distribution in a positive manner to help prevent obesity, making it a better candidate for 
overall health compared to tamoxifen. Its effects in relation to ApoE genotype have not 
been reported. 
3.6. Estradiol 
In post-menopausal estradiol (also known as 17β-estradiol or oestradiol) treatment is used 
for estrogen replacement therapy. Healthy post-menopausal women given estradiol 
display improved visuospatial abilities measured by a mental rotation task (Table 1) [49]. 
Other non-randomized studies in women with surgically induced amenorrhea or those 
with AD indicate that estrogen replacement treatment may help to improve or minimize 
cognitive deficits [50]. Even in men those given estradiol performed better on visual 
memory after treatment (Table 1) [51]. These results are consistent with improved memory 
in mice given other replacement estrogens treatments [52]. Over half of randomized clinical 
studies find significant improvements in cognition and attention after estrogen 
replacement therapy (Table 1) [53]. Estradiol has been shown to increase levels of ApoE in 
the brain, proposed to be beneficial for neuronal reorganization and repair [7]. In a health 
study of 3,393 women, results suggest that estrogen replacement reduces the risk of age-
related cognitive decline in non-ApoE4 women, but not in ApoE4 carriers (Table 1) [54]. 
Another study with 181 post-menopausal women, also found the best learning and 
memory performance after estrogen replacement is seen in non-ApoE4 carriers [55]. This 
suggests that knowing ApoE genotype may be helpful to assess potential response to 
estrogen replacement therapy.  
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Treatment Function Effects on 
Lipids/Apolipoproteins  
Effects on Cognition 
in rodent model 
operant learning 
paradigm. 
Letrozole Aromatase inhibitor 
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function. 
Increased serum total 
cholesterol, LDL and ApoB 






Exemestane Aromatase inhibitor 
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function. 





that had lower 
verbal and executive 
functioning. 
Raloxifene SERM, lowers 
estrogen function in 
reproductive tissue 




Lower cholesterol, LDL, ApoB 
protein levels and increases 
ApoA-1, HDL level leading to 
better cardiovascular health. 
Also shown to reduced 
adiposity and fat mass. 
Lowered the risk of 
cognitive decline or 
has no effect. 
Estradiol Estrogen 
replacement therapy 
Increase ApoE protein levels in 
brain. Reduces cognitive 




and visual memory. 
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replacement therapy 
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triglyceride levels, HDL and 
ApoA-1 levels. 
Decreased anxiety, 
improved quality of 
like and semantic 
memory. 
 
Cetrorelix Used to reduce 
gonadotrophins and 
sex steroids 









Table 1. Hormone treatments effects of lipids/apolipoproteins levels and cognition. 
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3.7. Tibolone 
Tibolone is another drug used in hormonal replacement therapy having estrogenic, 
progestogenic, and androgenic effects. Long-term treatment does appear to decrease 
anxiety, improve semantic memory and overall quality of life; however, one study reported 
that those in treatment did score worse on attention task compared to women not on 
treatment (Table 1) [56,57]. Tibolone appears to be the most beneficial with respect to 
reducing total cholesterol, triglyercide, HDL and ApoA-1 levels compared to raloxifene and 
estradiol (Table 1) [47,58-60]. This suggests that hormone replacement therapy with 
medications such as tibolone in post-menopausal women are beneficial to cognitive health 
and lipid profiles. 
3.8. Cetrorelix 
Cetrorelix an antagonist of hypothalamic luteinizing hormone-releasing hormone (LHRH), 
is used in treatment of prostate carcinoma, benign prostatic hyperplasia, and ovarian cancer 
to reduce gonadotrophins and sex steroids [61]. In mice, a study suggests that it is 
anxiolytic, anti-depressive and able to correct beta-amyloid 25-35 associated memory 
consolidation impairments (Table 1) [61]. Injection of cetrorelix into ApoE deficient mice 
(ApoE-/-) mice suggests that the associated suppression of testosterone leads to increased 
atherosclerosis despite lower cholesterol levels in the male mice [62]. In female ApoE-/- mice, 
the reduction in testosterone also leads to reduction in estradiol, insulin and HDL levels 
without effects on atherosclerosis [62]. In a pilot study conducted in men, treatment with 
cetrorelix resulted in increased ApoA-1, HDL, insulin and leptin consistently (Table 1) [63]. 
Therefore, when this drug is used within a chemotherapy treatment regiment it is important 
to carefully monitor lipid levels. Additional studies are needed to examine if ApoE genotype 
has any effect on response and potential long-term cognitive side effects of this drug. 
4. Recommendations 
1. Determine if an ApoE genotype can help assess what is most treatment useful including 
how to properly maintain lipid levels during chemotherapy. 
2. Find out lipid levels, track and maintain determined treatment to reduce risk of post-
chemotherapy cognitive impairments.  
3. Examine ApoE genotype before selecting pharmacotherapy options pre or post-
chemotherapy treatment. 
5. Conclusion 
Overall of the studies SERMs/aromatase inhibitors raloxifene or exemestane may be better 
alternatives to tamoxifen or letrozole treatment in terms of effects on cognitive deficits and 
overall health risk in women treated with chemotherapy. In addition, ApoE genotype and 
cholesterol levels need to be taken into account when examining efficacy of these drugs and 
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in hormone replacement therapies as efficacy is dependent on ApoE genotype. Knowing 
these issues will help doctors to address them early for improving quality of life, reducing 
services used and saving millions of dollars in unneeded medical expenses. Realistically, the 
wonder drug that can cure all cancer and has no side effects will not be found. What is 
needed is to reduce the impact and intensity of cognitive side-effects as much as possible, 
taking into account an individual’s physiology and genetics. The more we know about 
cognitive status across ages, ethnicity, lipid levels, and genetic status the better we can treat 
mind and body. 
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